Money Muscle

Money Muscle

Share this post

Money Muscle
Money Muscle
Supriya Lifescience FY25 Results: PAT up 58%, FY26 Targets 20% Growth with ₹1,000 Cr Revenue by FY27
Copy link
Facebook
Email
Notes
More

Supriya Lifescience FY25 Results: PAT up 58…

Money Muscle
May 29
6

Share this post

Money Muscle
Money Muscle
Supriya Lifescience FY25 Results: PAT up 58%, FY26 Targets 20% Growth with ₹1,000 Cr Revenue by FY27
Copy link
Facebook
Email
Notes
More
1

With new capacity online, Supriya targets ₹1,000 Cr revenue by FY27. High-margin APIs, CDMO growth, and rising ROE support upside despite elevated P/E.

Read →
Comments
User's avatar
© 2025 Money Muscle
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More